Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues

Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues

Histone deacetylase (HDAC) inhibitors are a class of drugs used in the cancer treatment. Here, we developed a library of 19 analogues of Vorinostat, an HDAC inhibitor used in lymphomas treatment. In Vorinostat, we replaced the hydrophobic phenyl group with various tricyclic ‘caps’ possessing a centr...

Full description

Bibliographic Details
Main Authors: Bartosz Bieszczad, Damian Garbicz, Marta Świtalska, Marta K. Dudek, Dawid Warszycki, Joanna Wietrzyk, Elżbieta Grzesiuk, Adam Mieczkowski
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceuticals
Subjects:
Vorinostat
histone deacetylase
HDAC inhibitors
dibenzodiazocines
hydroxamic acid
selectivity
Online Access:https://www.mdpi.com/1424-8247/14/9/851

Internet

https://www.mdpi.com/1424-8247/14/9/851

Similar Items